Effects of chronic treatment with citalopram on cannabinoid and opioid receptor-mediated G-protein coupling in discrete rat brain regions
- 217 Downloads
There is growing interest in investigating the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs), beyond their association with the serotonergic system, due to their wide therapeutic potential for disorders including depression, pain and addiction.
The aim of this study was to investigate whether chronic treatment with the SSRI, citalopram, alters the functional coupling of Gi/o-associated cannabinoid type 1 (CB1) and μ-opioid receptors in selected areas of rat brain implicated in psychiatric disorders and pain.
Using an autoradiographic approach, the effects of the cannabinoid receptor agonist, HU210 (in the presence or absence of the CB1 receptor antagonist AM251), or the μ-opioid receptor agonist, [d-Ala2,N–Me–Phe4,Gly5-ol]-enkephalin (DAMGO; in the presence or absence of the μ-opioid receptor antagonist d-Phe–Cys–Tyr-d-Trp–Orn–Thr–Pen–Thr–NH2), on [35S]GTPγS binding in discrete brain regions of citalopram-treated (10 mg kg−1 day−1 for 14 days by subcutaneous minipump) and control rats were investigated.
The HU210-induced increase in [35S]GTPγS binding observed in the hypothalamic paraventricular nucleus of control rats was abolished after chronic treatment with citalopram. Reduced response to HU210 in rats receiving chronic treatment with citalopram was also observed in the hippocampus and medial geniculate nucleus. Citalopram had no significant effect on DAMGO-induced [35S]GTPγS binding in the brain regions investigated, with the exception of the medial geniculate nucleus where a modest impairment was observed.
These data provide evidence for reduced cannabinoid receptor-mediated G-protein coupling in the hypothalamus, hippocampus and medial geniculate nucleus of rats chronically treated with citalopram, effects which may, in part, underlie the mechanism of action of SSRIs.
KeywordsAntidepressant Rat Cannabinoids Opioid receptor Paraventricular nucleus Hippocampus [35S]GTPγS autoradiography
This work was supported by Science Foundation Ireland and by a Research Visit Grant to SH from the British Society for Neuroendocrinology. We are grateful to Lundbeck plc, Copenhagen, for their kind gift of citalopram.
- Drew LJ, Harris J, Millns JP, Kendall DA, Chapman V (2000) Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPγS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci 12:2079–2086PubMedCrossRefGoogle Scholar
- Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB (2006) Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic–pituitary–adrenal axis. Neuropsychopharmacology 31:2591–2599PubMedCrossRefGoogle Scholar
- Murphy DL, Andrews AM, Wichems CH, Li Q, Tohda M, Greenberg B (1998) Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter system, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry 59(Suppl 15):4–12PubMedGoogle Scholar
- Paterson SJ, Robson LE, Kosterlitz HW (1988) Classification of opioid receptors. Br Med Bull 39:31–36Google Scholar
- Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, New YorkGoogle Scholar
- Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 138:544–553PubMedCrossRefGoogle Scholar